Shares of Beyondspring Inc (NASDAQ:BYSI) have received a consensus rating of “Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $35.00.
BYSI has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Beyondspring from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 target price (up from $30.00) on shares of Beyondspring in a research report on Monday, June 15th. Finally, ValuEngine upgraded Beyondspring from a “hold” rating to a “buy” rating in a report on Saturday, June 13th.
Shares of NASDAQ:BYSI opened at $11.03 on Tuesday. The stock’s 50-day moving average price is $14.76 and its two-hundred day moving average price is $15.07. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.44 and a quick ratio of 2.44. Beyondspring has a 12-month low of $9.38 and a 12-month high of $23.00.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BYSI. Goldman Sachs Group Inc. purchased a new position in shares of Beyondspring in the 4th quarter valued at $1,477,000. Russell Investments Group Ltd. purchased a new position in Beyondspring in the first quarter valued at about $471,000. BlackRock Inc. lifted its stake in shares of Beyondspring by 3.0% during the first quarter. BlackRock Inc. now owns 689,277 shares of the company’s stock worth $8,830,000 after purchasing an additional 19,930 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Beyondspring by 19.0% during the fourth quarter. Geode Capital Management LLC now owns 82,333 shares of the company’s stock worth $1,276,000 after purchasing an additional 13,120 shares in the last quarter. Finally, Alliancebernstein L.P. purchased a new stake in shares of Beyondspring in the first quarter worth about $140,000. Institutional investors own 6.60% of the company’s stock.
Beyondspring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Featured Article: Why do companies issue monthly dividends?
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.